AAO 2024: The Impact of New Data and Expanded Access for Underrepresented Populations in DME

Sunir J. Garg, MD

November 05, 2024

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing that high-dose aflibercept could effectively extend treatment intervals, reducing the burden on patients, particularly working-age adults with busy schedules.

Of note, research also confirmed that previously treated patients with DME benefit from these newer therapies, though they might need slightly more frequent treatment compared with treatment-naive patients. Dr Garg emphasizes the importance of equitable access to treatments, noting that patients from underrepresented backgrounds respond well to current therapies, and expresses optimism about gene therapy advances that could extend treatment intervals even further in the future.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: AAO 2024: The Impact of New Data and Expanded Access for Underrepresented Populations in DME - Medscape - Nov 05, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.